I. Zackon

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

J. Laubach, P. Richardson, S. Kroll, 2018, Clinical Cancer Research.

Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer

S. Grunberg, P. Unger, J. Valentine, 1995, Investigational New Drugs.

Hemorrhagic Cystitis Secondary to Adenovirus and BK Virus Infection in a Diffuse Large B-Cell Lymphoma Patient with Recent CAR T-Cell Therapy

Fatima Tuz Zahra, A. Ramani, A. M. Khan, 2020, Case reports in hematology.

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

J. Laubach, P. Richardson, P. Armand, 2014 .